Elpida Kontsioti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elpida Kontsioti has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Munir Pirmohamed
University of Liverpool Department of Pharmacology and Therapeutics
8 shared publications - Simon Maskell
University of Liverpool
6 shared publications Bhaskar Dutta
Patient Safety Center of Excellence AstraZeneca Gaithersburg MD USA
3 shared publicationsAmina Bensalem
R&D, Ceva Santé Animale Libourne France
2 shared publicationsSimon Maskell
University of Liverpool
2 shared publicationsIsobel Anderson
AstraZeneca UK Ltd
1 shared publication
Latest Publications
- 6 December 2025
- Published by Springer Nature in Drug Safety
- Vol. 49 (4) , 481-491
MCSG: A Method for Simultaneous Disproportionality Analysis and Background Rate Estimation in Large Pharmacovigilance Databases
Background Databases for safety monitoring of medicinal products contain records of a huge number of pairings of drugs and adverse events (AEs). Existing disproportionality methods for safety monitoring in such databases estimate background rates of AE occurrence in ways that may be susceptible to masking effects that can hinder signal detection, particularly in the context of large overall counts of AE or drug occurrence in the data. Objectives To develop a new statistical model for determining the background rate against which individual drug–AE pairs are to be evaluated, which is robust against masking effects, and to incorporate this into an algorithm which simultaneously estimates background rates and detects drug–AE pair counts that deviate significantly from these rates. Methods We constructed a hierarchical Bayesian model for background rates, and background rate samples were drawn from the model parameters using an iterative Markov Chain Monte Carlo (MCMC) method. At each iteration, any counts whose probability is low given current background rate estimation were removed from the computation that sampled the next set of background rates. The algorithm, called Markov Chain Signal Generation (MCSG), was implemented using a combination of Python and the probabilistic programming language Stan. Results The MCSG algorithm outperformed routinely used quantitative approaches for signal detection on both synthetic data designed to include a drug–AE pair with very strong masking effects and a reference set featuring 69 unique active substances and 792 unique AEs. On a synthetic dataset where selected pairs occurred at rates deviating from a constant background, MCSG accurately identified these pairs in the presence of strong masking signals. On a subset of some real data from the FDA Adverse Event Report System (FAERS), it effectively identified a reference set of positive and negative controls and was able to identify drug–AE pairs suggested in the literature. Conclusion We have demonstrated a new approach to signal generation, which avoids the confounding effect of masking more effectively than currently used methods. The algorithm is best used in a setting of multiple drug–AE pairs, the majority of which are expected to have counts at background rate, although with substantial datasets the algorithm can take minutes or hours to run. It is therefore particularly suitable for infrequent, large-scale analysis (for example, quarterly analysis of the entirety of a pharmacovigilance database).
- 6 December 2025
- Published by Springer Nature in Drug Safety
- Vol. 49 (4) , 481-491
MCSG: A Method for Simultaneous Disproportionality Analysis and Background Rate Estimation in Large Pharmacovigilance Databases
Background Databases for safety monitoring of medicinal products contain records of a huge number of pairings of drugs and adverse events (AEs). Existing disproportionality methods for safety monitoring in such databases estimate background rates of AE occurrence in ways that may be susceptible to masking effects that can hinder signal detection, particularly in the context of large overall counts of AE or drug occurrence in the data. Objectives To develop a new statistical model for determining the background rate against which individual drug–AE pairs are to be evaluated, which is robust against masking effects, and to incorporate this into an algorithm which simultaneously estimates background rates and detects drug–AE pair counts that deviate significantly from these rates. Methods We constructed a hierarchical Bayesian model for background rates, and background rate samples were drawn from the model parameters using an iterative Markov Chain Monte Carlo (MCMC) method. At each iteration, any counts whose probability is low given current background rate estimation were removed from the computation that sampled the next set of background rates. The algorithm, called Markov Chain Signal Generation (MCSG), was implemented using a combination of Python and the probabilistic programming language Stan. Results The MCSG algorithm outperformed routinely used quantitative approaches for signal detection on both synthetic data designed to include a drug–AE pair with very strong masking effects and a reference set featuring 69 unique active substances and 792 unique AEs. On a synthetic dataset where selected pairs occurred at rates deviating from a constant background, MCSG accurately identified these pairs in the presence of strong masking signals. On a subset of some real data from the FDA Adverse Event Report System (FAERS), it effectively identified a reference set of positive and negative controls and was able to identify drug–AE pairs suggested in the literature. Conclusion We have demonstrated a new approach to signal generation, which avoids the confounding effect of masking more effectively than currently used methods. The algorithm is best used in a setting of multiple drug–AE pairs, the majority of which are expected to have counts at background rate, although with substantial datasets the algorithm can take minutes or hours to run. It is therefore particularly suitable for infrequent, large-scale analysis (for example, quarterly analysis of the entirety of a pharmacovigilance database).
- Open Access
- 8 April 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 165-176
Identifying Drug–Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
Translational approaches can benefit post‐marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug–drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with drug‐target‐adverse event associations, 16.0% (AUC: from 0.580 to 0.673) with drug enzyme, and 15.0% (AUC: from 0.568 to 0.653) with drug transporter information. Applying this approach to detect potential DDI signals of QT prolongation and rhabdomyolysis within the FDA Adverse Event Reporting System (FAERS), we emphasize the significance of systems pharmacology in enhancing statistical signal detection in pharmacovigilance. Our study showcases the promise of data‐driven biological plausibility assessment in the context of challenging post‐marketing DDI surveillance.
- 8 April 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 165-176
Open AccessIdentifying Drug–Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
Translational approaches can benefit post‐marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug–drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with drug‐target‐adverse event associations, 16.0% (AUC: from 0.580 to 0.673) with drug enzyme, and 15.0% (AUC: from 0.568 to 0.653) with drug transporter information. Applying this approach to detect potential DDI signals of QT prolongation and rhabdomyolysis within the FDA Adverse Event Reporting System (FAERS), we emphasize the significance of systems pharmacology in enhancing statistical signal detection in pharmacovigilance. Our study showcases the promise of data‐driven biological plausibility assessment in the context of challenging post‐marketing DDI surveillance.
- Open Access
- 26 October 2023
- Published by Springer Nature in Research Square
Identifying drug-drug interactions in spontaneous reports utilizing signal detection and biological plausibility aspects
Translational approaches can benefit post-marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug-drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with drug-target-adverse event (AE) associations, 16.0% (AUC: from 0.580 to 0.673) with drug enzyme, and 15.0% (AUC: from 0.568 to 0.653) with drug transporter information. Applying this approach to detect potential DDI signals of QT prolongation and rhabdomyolysis within the FDA Adverse Event Reporting System (FAERS), we emphasize the significance of systems pharmacology in enhancing statistical signal detection in pharmacovigilance. Our study showcases the promise of data-driven biological plausibility assessment in the context of challenging post-marketing DDI surveillance.
- 26 October 2023
- Published by Springer Nature in Research Square
Open AccessIdentifying drug-drug interactions in spontaneous reports utilizing signal detection and biological plausibility aspects
Translational approaches can benefit post-marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug-drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with drug-target-adverse event (AE) associations, 16.0% (AUC: from 0.580 to 0.673) with drug enzyme, and 15.0% (AUC: from 0.568 to 0.653) with drug transporter information. Applying this approach to detect potential DDI signals of QT prolongation and rhabdomyolysis within the FDA Adverse Event Reporting System (FAERS), we emphasize the significance of systems pharmacology in enhancing statistical signal detection in pharmacovigilance. Our study showcases the promise of data-driven biological plausibility assessment in the context of challenging post-marketing DDI surveillance.
- Open Access
- 26 March 2023
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 32 (8) , 832-844
Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug–drug interactions
Purpose: To evaluate the impact of multiple design criteria for reference sets that are used to quantitatively assess the performance of pharmacovigilance signal detection algorithms (SDAs) for drug-drug interactions (DDIs).Methods: Starting from a large and diversified reference set for two-way DDIs, we generated custom-made reference sets of various sizes considering multiple design criteria (e.g., adverse event background prevalence). We assessed differences observed in the performance metrics of three SDAs when applied to FDA Adverse Event Reporting System (FAERS) data.Results: For some design criteria, the impact on the performance metrics was neglectable for the different SDAs (e.g., theoretical evidence associated with positive controls), while others (e.g., restriction to designated medical events, event background prevalence) seemed to have opposing and effects of different sizes on the Area Under the Curve (AUC) and positive predictive value (PPV) estimates.Conclusions: The relative composition of reference sets can significantly impact the evaluation metrics, potentially altering the conclusions regarding which methodologies are perceived to perform best. We therefore need to carefully consider the selection of controls to avoid misinterpretation of signals triggered by confounding factors rather than true associations as well as adding biases to our evaluation by "favoring" some algorithms while penalizing others.
- 26 March 2023
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 32 (8) , 832-844
Open AccessExploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug–drug interactions
Purpose: To evaluate the impact of multiple design criteria for reference sets that are used to quantitatively assess the performance of pharmacovigilance signal detection algorithms (SDAs) for drug-drug interactions (DDIs).Methods: Starting from a large and diversified reference set for two-way DDIs, we generated custom-made reference sets of various sizes considering multiple design criteria (e.g., adverse event background prevalence). We assessed differences observed in the performance metrics of three SDAs when applied to FDA Adverse Event Reporting System (FAERS) data.Results: For some design criteria, the impact on the performance metrics was neglectable for the different SDAs (e.g., theoretical evidence associated with positive controls), while others (e.g., restriction to designated medical events, event background prevalence) seemed to have opposing and effects of different sizes on the Area Under the Curve (AUC) and positive predictive value (PPV) estimates.Conclusions: The relative composition of reference sets can significantly impact the evaluation metrics, potentially altering the conclusions regarding which methodologies are perceived to perform best. We therefore need to carefully consider the selection of controls to avoid misinterpretation of signals triggered by confounding factors rather than true associations as well as adding biases to our evaluation by "favoring" some algorithms while penalizing others.
- Open Access
- 12 April 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (9) , 4067-4079
Similarity and consistency assessment of three major online drug–drug interaction resources
Aims: The aim of this study was to explore the level of agreement on drug–drug interaction (DDI) information listed in three major online drug information resources (DIRs) in terms of: (1) interacting drug pairs; (2) severity rating; (3) evidence rating; and (4) clinical management recommendations.Methods: We extracted information from the British National Formulary (BNF), Thesaurus and Micromedex. Following drug name normalisation, we estimated the overlap of the DIRs in terms of DDI. We annotated clinical management recommendations either manually, where possible, or through application of a machine learning algorithm.Results: The DIRs contained 51 481 (BNF), 38 037 (Thesaurus) and 65 446 (Micromedex) drug pairs involved in DDIs. The number of common DDIs across the three DIRs was 6970 (13.54% of BNF, 18.32% of Thesaurus and 10.65% of Micromedex). Micromedex and Thesaurus overall showed higher levels of similarity in their severity ratings, while the BNF agreed more with Micromedex on the critical severity ratings and with Thesaurus on the least significant ones. Evidence rating agreement between BNF and Micromedex was generally poor. Variation in clinical management recommendations was also identified, with some categories (i.e., Monitor and Adjust dose) showing higher levels of agreement compared to others (i.e., Use with caution, Wash‐out, Modify administration).Conclusions: There is considerable variation in the DDIs included in the examined DIRs, together with variability in categorisation of severity and clinical advice given. DDIs labelled as critical were more likely to appear in multiple DIRs. Such variability in information could have deleterious consequences for patient safety, and there is a need for harmonisation and standardisation.
- 12 April 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (9) , 4067-4079
Open AccessSimilarity and consistency assessment of three major online drug–drug interaction resources
Aims: The aim of this study was to explore the level of agreement on drug–drug interaction (DDI) information listed in three major online drug information resources (DIRs) in terms of: (1) interacting drug pairs; (2) severity rating; (3) evidence rating; and (4) clinical management recommendations.Methods: We extracted information from the British National Formulary (BNF), Thesaurus and Micromedex. Following drug name normalisation, we estimated the overlap of the DIRs in terms of DDI. We annotated clinical management recommendations either manually, where possible, or through application of a machine learning algorithm.Results: The DIRs contained 51 481 (BNF), 38 037 (Thesaurus) and 65 446 (Micromedex) drug pairs involved in DDIs. The number of common DDIs across the three DIRs was 6970 (13.54% of BNF, 18.32% of Thesaurus and 10.65% of Micromedex). Micromedex and Thesaurus overall showed higher levels of similarity in their severity ratings, while the BNF agreed more with Micromedex on the critical severity ratings and with Thesaurus on the least significant ones. Evidence rating agreement between BNF and Micromedex was generally poor. Variation in clinical management recommendations was also identified, with some categories (i.e., Monitor and Adjust dose) showing higher levels of agreement compared to others (i.e., Use with caution, Wash‐out, Modify administration).Conclusions: There is considerable variation in the DDIs included in the examined DIRs, together with variability in categorisation of severity and clinical advice given. DDIs labelled as critical were more likely to appear in multiple DIRs. Such variability in information could have deleterious consequences for patient safety, and there is a need for harmonisation and standardisation.
- Open Access
- 4 March 2022
- Published by Springer Nature in Scientific Data
- Vol. 9 (1) , 1-9
A reference set of clinically relevant adverse drug-drug interactions
The accurate and timely detection of adverse drug-drug interactions (DDIs) during the postmarketing phase is an important yet complex task with potentially major clinical implications. The development of data mining methodologies that scan healthcare databases for drug safety signals requires appropriate reference sets for performance evaluation. Methodologies for establishing DDI reference sets are limited in the literature, while there is no publicly available resource simultaneously focusing on clinical relevance of DDIs and individual behaviour of interacting drugs. By automatically extracting and aggregating information from multiple clinical resources, we provide a scalable approach for generating a reference set for DDIs that could support research in postmarketing safety surveillance. CRESCENDDI contains 10,286 positive and 4,544 negative controls, covering 454 drugs and 179 adverse events mapped to RxNorm and MedDRA concepts, respectively. It also includes single drug information for the included drugs (i.e., adverse drug reactions, indications, and negative drug-event associations). We demonstrate usability of the resource by scanning a spontaneous reporting system database for signals of DDIs using traditional signal detection algorithms.
- 4 March 2022
- Published by Springer Nature in Scientific Data
- Vol. 9 (1) , 1-9
Open AccessA reference set of clinically relevant adverse drug-drug interactions
The accurate and timely detection of adverse drug-drug interactions (DDIs) during the postmarketing phase is an important yet complex task with potentially major clinical implications. The development of data mining methodologies that scan healthcare databases for drug safety signals requires appropriate reference sets for performance evaluation. Methodologies for establishing DDI reference sets are limited in the literature, while there is no publicly available resource simultaneously focusing on clinical relevance of DDIs and individual behaviour of interacting drugs. By automatically extracting and aggregating information from multiple clinical resources, we provide a scalable approach for generating a reference set for DDIs that could support research in postmarketing safety surveillance. CRESCENDDI contains 10,286 positive and 4,544 negative controls, covering 454 drugs and 179 adverse events mapped to RxNorm and MedDRA concepts, respectively. It also includes single drug information for the included drugs (i.e., adverse drug reactions, indications, and negative drug-event associations). We demonstrate usability of the resource by scanning a spontaneous reporting system database for signals of DDIs using traditional signal detection algorithms.
- Open Access
- 22 November 2021
- Published by Wiley
Similarity and Consistency Assessment of Three Major Online Drug-Drug Interaction Resources
AIM: To explore the level of agreement on drug-drug interaction (DDI) information listed in three major online drug information resources (DIRs) in terms of: (1) interacting drug pairs; (2) severity rating; (3) evidence rating and (4) clinical management recommendations. METHODS: We extracted DDI information from the British National Formulary (BNF), Thesaurus, and Micromedex. Following drug name normalisation, we estimated the overlap of the DIRs. We annotated clinical management recommendations either manually, where possible, or through application of a machine learning algorithm. RESULTS: The DIRs contained 51,481 (BNF), 38,037 (Thesaurus), and 65,446 (Micromedex) drug pairs involved in DDIs. The number of common DDIs across the three DIRs was 6,970 (13.54% of BNF, 18.32% of Thesaurus, and 10.65% of Micromedex). Micromedex and Thesaurus overall showed higher levels of similarity in their severity ratings, while the BNF agreed more with Micromedex on the critical severity ratings and with Thesaurus on the least significant ones. Evidence rating agreement between BNF and Micromedex was generally poor. Variation in clinical management recommendations was also identified, with some categories (i.e. Monitor and Adjust dose) showing higher levels of agreement compared to others (i.e. Use with caution, Wash-out, Modify administration). CONCLUSIONS: There is considerable variation in the DDIs included in the examined DIRs, together with variability in categorisation of severity and clinical advice given. DDIs labelled as critical are more likely to appear in multiple DIRs. Such variability in information could have deleterious consequences for patient safety, and there is a need for harmonisation and standardisation.
- 22 November 2021
- Published by Wiley
Open AccessSimilarity and Consistency Assessment of Three Major Online Drug-Drug Interaction Resources
AIM: To explore the level of agreement on drug-drug interaction (DDI) information listed in three major online drug information resources (DIRs) in terms of: (1) interacting drug pairs; (2) severity rating; (3) evidence rating and (4) clinical management recommendations. METHODS: We extracted DDI information from the British National Formulary (BNF), Thesaurus, and Micromedex. Following drug name normalisation, we estimated the overlap of the DIRs. We annotated clinical management recommendations either manually, where possible, or through application of a machine learning algorithm. RESULTS: The DIRs contained 51,481 (BNF), 38,037 (Thesaurus), and 65,446 (Micromedex) drug pairs involved in DDIs. The number of common DDIs across the three DIRs was 6,970 (13.54% of BNF, 18.32% of Thesaurus, and 10.65% of Micromedex). Micromedex and Thesaurus overall showed higher levels of similarity in their severity ratings, while the BNF agreed more with Micromedex on the critical severity ratings and with Thesaurus on the least significant ones. Evidence rating agreement between BNF and Micromedex was generally poor. Variation in clinical management recommendations was also identified, with some categories (i.e. Monitor and Adjust dose) showing higher levels of agreement compared to others (i.e. Use with caution, Wash-out, Modify administration). CONCLUSIONS: There is considerable variation in the DDIs included in the examined DIRs, together with variability in categorisation of severity and clinical advice given. DDIs labelled as critical are more likely to appear in multiple DIRs. Such variability in information could have deleterious consequences for patient safety, and there is a need for harmonisation and standardisation.